Mackenzie Financial
CLSD

Mackenzie Financial’s Clearside Biomedical CLSD Stock Holding History

Mackenzie Financial’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,911
Closed -$32.4K – 1490
2023
Q2 		$32.4K Hold
1,911
– – ﹤0.01% 1484
2023
Q1 		$29.8K Sell
1,911
-307
-14% -$5.96K ﹤0.01% 1468
2022
Q4 		$37.3K Sell
2,218
-411
-16% -$7.4K ﹤0.01% 1376
2022
Q3 		$45K Buy
2,629
+399
+18% +$8.74K ﹤0.01% 1364
2022
Q2 		$49K Buy
2,230
+1,446
+184% +$35.1K ﹤0.01% 1397
2022
Q1 		$27K Buy
+784
New +$23.5K ﹤0.01% 1389

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mackenzie Financial's CLSD Position: Q3 2023 in Review

Mackenzie Financial sold out of Clearside Biomedical (CLSD) in Q3 2023, closing a stake of 1,911 shares — an estimated $32.4K sold.

Mackenzie Financial first reported a position in CLSD in Q1 2022 and held it in 6 quarters. The position peaked at $49K in Q2 2022. 45 funds tracked by Wall St. Rank hold CLSD as of Q3 2023.

  • Mackenzie Financial reported no remaining Clearside Biomedical position as of Q3 2023 after selling out during the quarter.
  • Mackenzie Financial sold 1,911 Clearside Biomedical shares in Q3 2023, an estimated $32.4K.
  • Mackenzie Financial first reported a position in Clearside Biomedical in Q1 2022 and held it in 6 quarters.
  • Mackenzie Financial's Clearside Biomedical position peaked at $49K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2023.

Based on Mackenzie Financial's 13F filing for Q3 2023, filed 25 Oct 2023.